Article
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.
AIDS (London, England) - 14 Oct 2005
Ghosn Jade, Wirden Marc, Ktorza Nadine, Peytavin Gilles, Aït-Mohand Hocine, Schneider Luminita, Dominguez Stéphanie, Bricaire François, Calvez Vincent, Costagliola Dominique, Katlama Christine
Abstract excerpt
OBJECTIVE: To evaluate the potential benefits of a tailored antiretroviral treatment interruption with duration based on the observed reversion of resistance mutations. METHODS: In this open single-arm pilot study, 23 patients with multiple treatment failure interrupted therapy and underwent longitudinal genotypic resistance testing. Salvage gigatherapy was started when resistance mutations to at least two...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
